ABIONYX Pharma Provides an Update on Its Business and Cash …

1 day ago · Cash position of €4.1m before receipt of IRIS Pharma’s CIR (€610k) as of September 30, 2024 Live broadcast of the General Meeting on November 28, 2024, at 2.00 pm CET …

€4
OFF

ABIONYX Pharma Provides An Update On Its Business And Cash …

2 weeks from now

1 day ago · Cash position of €4.1m before receipt of IRIS Pharma’s CIR (€610k) as of September 30, 2024 Live broadcast of the General Meeting on November 28, 2024, at 2.00 pm CET …

businesswire.com

€5
OFF

ABIONYX Pharma Provides An Update On Its Business And Cash …

2 weeks from now

Cash position of €5.3m before IRIS Pharma CIR (€610k) at June 30, 2024. TOULOUSE, France & LAKELAND, Mich., August 22, 2024 -- (BUSINESS WIRE)--Regulatory News: ABIONYX …

yahoo.com

€5
OFF

ABIONYX Pharma Provides An Update On Its Business And …

2 weeks from now

s to provide its bioproduct free of charge as part of its compassionate access applications.At June 30, 2024, ABIONYX Pharma's cash position reached €5.3m, including the reimb. rsement of …

abionyx.com

€5
OFF

ABIONYX Pharma Provides An Update On Its Business And Cash …

2 weeks from now

Aug 22, 2024 · ABIONYX Pharma provides an update on its business and cash position for the 1 st half of 2024. ... At June 30, 2024, ABIONYX Pharma's cash position reached €5.3m, …

businesswire.com

€1
OFF

ABIONYX Pharma Provides An Update On Its Business And …

2 weeks from now

1/2 Press release ABIONYX Pharma provides an update on its business and cash position for the first half of 2023 • Cash of €1.9 million (excluding Research Tax Credit) as of June 30, 2023 …

abionyx.com

€2
OFF

ABIONYX Pharma Provides An Update On Its Business And Cash …

2 weeks from now

Aug 22, 2024 · ABIONYX Pharma provides an update on its business and cash position for the 1 st half of 2024. Consolidated sales of €2.4m at end June 2024; Cash position of €5.3m before …

morningstar.com

€2
OFF

ABIONYX Pharma Provides An Update On Its Business And Cash …

2 weeks from now

Jun 30, 2024 · Issuer. ABIONYX PHARMA. Consolidated sales of €2.4m at end June 2024. Cash position of €5.3m before IRIS Pharma CIR (€610k) at June 30, 2024. Regulatory News: …

euronext.com

€1
OFF

ABIONYX Pharma Provides An Update On Its Activity And Its …

2 weeks from now

ApoA-I, today provides an update on its activity and cash position as of March 31, 2023. ABIONYX Pharma recorded consolidated quarterly revenue of €1,09 million after elimination of …

abionyx.com

€675
OFF

ABIONYX Pharma Provides An Update On Its Business And Cash …

2 weeks from now

Feb 24, 2022 · Consolidated revenue in 2021 including the firstmonth of activity from IRIS Pharma: €675K. Cash position of €7.9 million as of December 31, 2021. Continued …

businesswire.com

€3
OFF

ABIONYX Pharma Provides An Update On Its Activity, Its Revenue …

2 weeks from now

This cash position does not include the €3 million capital increase carried out by ABIONYX Pharma on October 6, 2023, or the reimbursement of IRIS Pharma's French Tax Credit (CIR) …

yahoo.com

€2
OFF

ABIONYX Pharma Provides An Update On Its Business And Cash …

2 weeks from now

Jun 30, 2024 · Selected financial information (IFRS) ABIONYX Pharma recorded consolidated half-year sales of €2.4m for the first half of 2024, compared with €2.1m for the first half of …

streetinsider.com

€3
OFF

ABIONYX Pharma Provides An Update On Its Business And Cash …

2 weeks from now

11 hours ago · Consolidated revenue of €3.4m at the end of September 2024 Cash position of €4.1m before receipt of IRIS Pharma's CIR (€610k) as of September 30, 2024 Live broadcast …

finanznachrichten.de

€3
OFF

ABIONYX Pharma Provides An Update On Its Business And Cash

2 weeks from now

1 day ago · Consolidated revenue of €3.4m at the end of September 2024 Cash position of €4.1m before receipt of IRIS Pharma’s CIR (€610k) as of...

advfn.com

FAQs about ABIONYX Pharma Provides an Update on Its Business and Cash … Coupon?

What was abionyx pharma's cash position at June 30 2024?

At June 30, 2024, ABIONYX Pharma's cash position reached €5.3m, including the reimbursement of the Abionyx CIR (€770k) and before the reimbursement of the IRIS CIR (€610k). ...

Is abionyx Pharma a PME eligible company?

ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only natural recombinant ApoA-I, today provided an update on its business and cash position for the 1 st half to June 30, 2023. ...

What is abionyx Pharma?

ABIONYX Pharma is a next-generation biotech company focused on developing innovative medicines for diseases where there is no effective or existing treatment, even the rarest ones. The company expedites the development of novel therapeutics through an extensive expertise in lipid science and a differentiated apoA-I-based technology platform. ...

Did abionyx Pharma generate sales in the first half?

With regard to the discovery and development of innovative therapies designed to improve patients' lives, the Company did not generate any sales in the first half, as ABIONYX Pharma continues to provide its bioproduct free of charge as part of its compassionate access applications. ...

What is abionyx Pharma apotherapy & biovectorization?

ABIONYX Pharma is developing two innovative technological platforms: apotherapy only based on the apoA-I and biovectorization using apoA-I complexes as a vector to deliver several active ingredients. These two platforms have multiple possible applications in ophthalmology. ...